PETALUMA, Calif., Jul 29, 2008 (BUSINESS WIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that the financial results for its fiscal first quarter ended June 30, 2008, will be released after the U.S. market closes on August 5, 2008. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on August 5, 2008, to discuss fiscal first quarter results and provide a corporate update to the investment community.
Individuals interested in participating in the conference call may do so by dialing (800) 232-9476 for domestic callers or (706) 679-2532 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.
A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 57954211. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India, Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers.
In addition to the company's existing and under-development therapeutic products, Oculus also develops, manufactures and markets a number of 510k devices and products for both professional and consumer. Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan. More information can be found at the company's web site, www.oculusis.com.
SOURCE: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc. Director of Public and Investor Relations Dan McFadden, 425-753-2105 email@example.com or Lippert/Heilshorn & Associates, Inc. Investors: Bruce Voss/Don Markley, 310-691-7100 firstname.lastname@example.org email@example.com or Media: Jules Abraham, 212-838-3777 firstname.lastname@example.org
Copyright Business Wire 2008
News Provided by COMTEX